Alibaba Tirzepatide: What the Evidence and Regulators Say

What official guidance actually says about tirzepatide bought outside the licensed supply chain

NICE's appraisal of tirzepatide, TA1026, is built on evidence from rigorously controlled clinical trials in which every participant received medicine from the authorised manufacturing chain, with appropriate storage, cold-chain handling, and prescriber oversight. The trial results that make tirzepatide notable (average body-weight reductions of around 20–21% at the highest dose over 72 weeks in SURMOUNT-1) were produced under those conditions. A pen of uncertain origin, stored at unknown temperatures, with unknown contents, cannot be expected to replicate them.

The MHRA has been explicit about what goes wrong in practice. In October 2025, enforcement teams raided a site in Northampton that was producing counterfeit tirzepatide pens domestically, these were not grey-market imports mishandled in transit, but locally manufactured fakes, indistinguishable in appearance from genuine Mounjaro. Previous operations found counterfeit GLP-1 pens containing insulin, which carries an immediate risk of life-threatening hypoglycaemia if injected by someone without diabetes. Alibaba and similar platforms are wholesale-facing marketplaces with sellers operating across multiple jurisdictions; they cannot offer the prescriber assessment, cold-chain integrity, or pharmacy regulation that a UK-licensed medicine requires.

Concerns about this supply route can be reported directly through the MHRA Yellow Card scheme, which covers both adverse drug reactions and suspected counterfeit or illegally sold medicines.

Why the price difference on marketplace listings does not reflect a bargain

Listings for tirzepatide on wholesale or consumer marketplaces often appear dramatically cheaper than private pharmacy prices. The reason is not a more efficient supply chain. It reflects the absence of the things that make a medicine safe: a licensed prescriber's clinical review, pharmacy dispensing checks, authenticated product from an authorised Eli Lilly distributor, cold-chain logistics with temperature monitoring, and regulatory accountability if something goes wrong.

Since September 2025, Eli Lilly raised the UK list price of higher-dose Mounjaro pens substantially, reports indicate the highest-dose pen moved from around £122 to around £330 per four-week pen. Private pharmacy prices since then have typically ranged from roughly £149 to £375 per month depending on dose and provider, with lower dose options such as tirzepatide 10 sitting toward the more accessible end of that range. A marketplace listing sitting far below that range is not exempt from Eli Lilly's supply economics; it is drawing from a different, unverified source.

For more context on how private treatment pricing works (and what a legitimate price actually covers) the tirzepatide cost and access overview sets out the full picture, including what to look for when comparing providers.

How to access tirzepatide through a verified UK route

The legal pathway is a private prescription following a clinical assessment by a UK-registered prescriber, dispensed by a GPhC-registered pharmacy that sources from the licensed UK supply chain. Every pharmacy that is legally entitled to dispense prescription medicines in the UK appears on the GPhC register, verifiable in seconds at pharmacyregulation.org/registers. If a seller cannot be found there, it is not a registered UK pharmacy.

At nume, consultations are reviewed the same day by a named, GPhC-registered Independent Prescriber, a real clinician reading your answers, not automated software. Supply comes through Eli Lilly's authorised UK distributor, stored and dispatched under the conditions the product requires. There are no subscriptions, and every repeat order goes through a fresh clinical review, including for patients titrating up to higher doses such as tirzepatide 30. Details of how the process works step by step are on the Mounjaro treatment page.

If you are weighing up whether tirzepatide is clinically right for you at all, the tirzepatide information page covers the evidence, licensed eligibility criteria, and what the prescribing process involves. People who are currently on treatment elsewhere and want to understand the comparison between options may find the Mounjaro and tirzepatide guide a useful starting point.

When you are ready, a free consultation with our prescribers is the right next step.